Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia

Purpose Tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukaemia have been reported to induce immunomodulatory effects. We aimed to assess peripheral blood (PB) and bone marrow (BM) lymphocyte status at the diagnosis and during different TKI therapies and correlate it wit...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and clinical oncology 2016-05, Vol.142 (5), p.1041-1050
Main Authors: El Missiry, Mohamed, Adnan Awad, Shady, Rajala, Hanna L, Al-Samadi, Ahmed, Ekblom, Marja, Markevän, Berit, Åstrand-Grundström, Ingbritt, Wold, Maren, Svedahl, Ellen Rabben, Juhl, Birgitte Ravn, Bjerrum, Ole Weis, Haulin, Inger, Porkka, Kimmo, Olsson-Strömberg, Ulla, Hjorth-Hansen, Henrik, Mustjoki, Satu
Format: Article
Language:English
Subjects:
Bone marrow
Bone Marrow - drug effects
Bone Marrow - immunology
Bone Marrow - pathology
Cancer Research
Clinical outcomes
CML
Cytogenetic Analysis
Cytotoxicity, Immunologic
Dasatinib - therapeutic use
Flow Cytometry
Hematology
Humans
Immune System - drug effects
Immune System - immunology
Immune System - pathology
Immunophenotyping
Inhibitor drugs
Internal Medicine
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology
Lymphocyte
Lymphocytes
Lymphocytes - drug effects
Lymphocytes - immunology
Lymphocytes - pathology
Medicine
Medicine & Public Health
Oncology
Original Article – Clinical Oncology
Phenotype
Prognosis
Protein Kinase Inhibitors - therapeutic use
Protein-Tyrosine Kinases - antagonists & inhibitors
Therapy response
Tyrosine kinase inhibitor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukaemia have been reported to induce immunomodulatory effects. We aimed to assess peripheral blood (PB) and bone marrow (BM) lymphocyte status at the diagnosis and during different TKI therapies and correlate it with treatment responses. Methods BM and PB samples were acquired from 105 first-line TKI-treated patients. Relative number of BM lymphocytes was evaluated from MGG-stained BM aspirates, and immunophenotypic analyses were performed with multicolour flow cytometry. Results Early 3-month expansion of BM lymphocytes was found during all different TKIs (imatinib n  = 71, 20 %; dasatinib n  = 25, 21 %; nilotinib n  = 9, 22 %; healthy controls n  = 14, 12 %, p  
ISSN:0171-5216
1432-1335
1432-1335
DOI:10.1007/s00432-015-2101-4